Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalOncotarget
Volume2
Issue number1-2
StatePublished - Jan 2011

Fingerprint

Cell Aging
Neoplasms
Excipients
Helper-Inducer T-Lymphocytes
Research
Microtubules
Doxorubicin
DNA Damage
Transcription Factors
Growth
Pharmaceutical Preparations

Keywords

  • 4e-bp1
  • Discodermolide
  • Mtorc1
  • P53
  • Senescence

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. / Chao, Suzan K.; Band Horwitz, Susan; McDaid, Hayley M.

In: Oncotarget, Vol. 2, No. 1-2, 01.2011, p. 89-98.

Research output: Contribution to journalArticle

@article{51751949261445098807d1990e08d602,
title = "Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence",
abstract = "Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.",
keywords = "4e-bp1, Discodermolide, Mtorc1, P53, Senescence",
author = "Chao, {Suzan K.} and {Band Horwitz}, Susan and McDaid, {Hayley M.}",
year = "2011",
month = "1",
language = "English (US)",
volume = "2",
pages = "89--98",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1-2",

}

TY - JOUR

T1 - Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence

AU - Chao, Suzan K.

AU - Band Horwitz, Susan

AU - McDaid, Hayley M.

PY - 2011/1

Y1 - 2011/1

N2 - Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.

AB - Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.

KW - 4e-bp1

KW - Discodermolide

KW - Mtorc1

KW - P53

KW - Senescence

UR - http://www.scopus.com/inward/record.url?scp=79959238659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959238659&partnerID=8YFLogxK

M3 - Article

C2 - 21399233

AN - SCOPUS:79959238659

VL - 2

SP - 89

EP - 98

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1-2

ER -